Telix Pharmaceuticals (ASX:TLX) and United Imaging Healthcare North America entered into a memorandum of understanding (MOU) to evaluate a strategic research partnership in the US focused on developing integrated theranostics technologies that combine diagnostics and targeted therapy, Telix said Tuesday after hours.
The partnership will evaluate integrating United Imaging's imaging systems, software, connectivity, and artificial intelligence (AI) tools with the company's molecular imaging portfolio and clinical protocols to enhance theranostic workflows.
Key focus areas include improving integration of imaging and radiopharmaceutical workflows, standardizing protocol-driven imaging across sites, enhancing treatment planning and patient monitoring, and developing AI-enabled clinical decision support tools.
The initial focus will be on TLX101-Px, a positron emission tomography imaging candidate, with opportunities to expand into additional products and markets, as well as pilot programs and protocol optimization efforts.